中国乳腺癌重要基础转化研究——进展与展望

卢愚风, 王晗, 谢亦璠, 江一舟, 邵志敏

  1. 复旦大学附属肿瘤医院乳腺外科/复旦大学乳腺癌研究所,复旦大学上海医学院肿瘤学系,上海 200032
  • 收稿日期:2024-12-30 修回日期:2025-01-24 出版日期:2025-02-28 发布日期:2025-03-19
  • 通信作者: 邵志敏
  • 作者简介:卢愚风(ORCID: 0009-0005-7396-4702),复旦大学附属肿瘤医院博士研究生。
    邵志敏,主任医师,教授,首批教育部长江学者特聘教授,国家杰出青年科学基金项目获得者,复旦大学特聘教授,复旦大学肿瘤研究所所长,复旦大学乳腺癌研究所所长,复旦大学附属肿瘤医院大外科主任兼乳腺外科主任。担任中华医学会肿瘤学分会副主任委员、中国抗癌协会乳腺癌专业委员会名誉主任委员、中国抗癌协会肿瘤靶向治疗专业委员会主任委员、第八届亚洲乳腺癌协会主席,连续四届担任圣加仑国际乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,确立乳腺癌“复旦分型”和精准治疗策略,开展临床试验改善患者预后。在JAMA、BMJ、Cancer Cell、Nature Genetics、Cell Metabolism、Lancet Oncology、Journal of Clinical Oncology、JAMA Oncology等重要期刊上发表多篇论文,主编专著10部。先后获得国家科技进步二等奖,教育部科技进步一、二等奖,卫健委科技进步一等奖,上海市科技进步一、二、三等奖,领衔团队入选教育部创新团队。先后主持国家自然科学基金重大项目、国家自然科学基金专项项目、国家卫健委临床重点项目等国家级及省部级项目。
  • 基金资助:
    国家自然科学基金(U24A20736);国家自然科学基金(82425044)

摘要/Abstract

摘要:

乳腺癌作为威胁中国女性健康的常见恶性肿瘤之一,其发病率和死亡率正持续攀升。面对这一严峻形势,迫切需要通过基础转化研究来优化治疗方案,以应对当前治疗中存在的挑战。本文综述中国近5年在乳腺癌基础转化研究领域的关键进展,旨在为乳腺癌的精准治疗提供科学依据和新方向。研究涵盖乳腺癌的分子分型、生物标志物发掘、耐药机制探索、精准治疗策略优化以及新靶点的鉴别等多个方面。在分子分型方面,研究者通过深入分析乳腺癌亚型,揭示了不同亚型在治疗响应上的显著差异,并针对各亚型提出了特定的治疗策略,为实现个体化治疗奠定了理论基础。生物标志物的发掘为患者选定合适的治疗方案提供了重要依据。研究显示,利用液体活检和蛋白质组学技术,已发现多个有前景的生物标志物,为乳腺癌的早期诊断和预后评估带来了新希望。在耐药机制的研究中,研究者们揭示了内分泌治疗和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)靶向治疗耐药的分子机制,并提出了逆转耐药的潜在策略,为提升治疗效果开辟了新途径。在免疫治疗和靶向治疗领域,新靶点和生物标志物的识别为乳腺癌治疗提供了新的视角。基于对肿瘤异质性的深入理解,科研人员通过多组学分析不断优化精准治疗策略,为乳腺癌患者提供了更为个性化的治疗方案。同时,新技术的应用也在持续推动乳腺癌精准治疗的发展。例如,人工智能技术在乳腺癌的早期筛查、诊断、疗效评估及预后预测中展现出巨大潜力。另一方面,通过纳米技术开发新型药物递送系统,提高了药物的靶向性和疗效。此外,水凝胶贴片技术和肿瘤疫苗的研究为乳腺癌的治疗提供了新策略。总体而言,中国在乳腺癌基础转化研究领域取得了显著成就,这些研究成果不仅加深了我们对乳腺癌分子机制的理解,也为未来治疗策略的发展带来希望。随着多学科融合的推进和新兴技术的应用,精准治疗有望为乳腺癌患者带来更多获益。

关键词: 乳腺癌, 基础转化研究, 耐药机制, 精准治疗, 生物标志物, 免疫治疗

Abstract:

Breast cancer is the most prevalent malignant tumor that poses a threat to women's health in China, with incidence and mortality rates persistently increasing. Given this critical situation, there is an urgent need to optimize therapeutic options through basic translational research to address current treatment challenges. This article provided a comprehensive overview of the significant advancements in fundamental translational breast cancer research in China over the past five years, aiming to provide a scientific basis and new directions for precision treatment of breast cancer. This research encompasses a range of subjects, including molecular typing, biomarker identification, exploration of drug resistance mechanisms, optimization of precision treatment strategies, and identification of new targets in breast cancer. In the domain of molecular typing, researchers have revealed substantial disparities in treatment responses among distinct subtypes of breast cancer through in-depth analysis. This has led to the proposal of specific therapeutic strategies for each subtype, thereby establishing a robust theoretical foundation for individualized treatment approaches. The identification of biomarkers plays a pivotal role in selecting appropriate treatment options for patients. Recent research advancements have demonstrated the potential of liquid biopsy and proteomics technologies in uncovering promising biomarkers, offering novel prospects for the early diagnosis and prognostic assessment of breast cancer. In the investigation of resistance mechanisms, researchers have elucidated the molecular underpinnings of resistance to endocrine therapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy and proposed potential strategies to overcome resistance. This has paved the way for novel approaches to enhance therapeutic efficacy. In the context of immunotherapy and targeted therapies, the discernment of novel targets and biomarkers has facilitated novel perspectives on breast cancer treatment. Based on advanced comprehension of tumor heterogeneity, researchers constantly optimize precision treatment strategies through multiomics analysis, thus offering patients with breast cancer enhanced personalized treatment options. Concurrently, the implementation of novel technologies has been instrumental in facilitating the advancement of precision treatment for breast cancer. For instance, the application of artificial intelligence technology has demonstrated considerable potential in the early screening, diagnosis, efficacy assessment and prognosis prediction of breast cancer. Conversely, the advent of innovative drug delivery systems facilitated by nanotechnology has led to enhanced targeting and efficacy of pharmaceutical agents. Furthermore, research into hydrogel patch technology and tumor vaccines has yielded novel strategies for the treatment of breast cancer. Overall, China has accomplished remarkable achievements in the field of basic translational research on breast cancer. These findings not only enhance our understanding of the molecular mechanisms of breast cancer, but also provide new directions and hope for the development of future therapeutic strategies. With the advancement of multidisciplinary integration and the application of new emerging technologies, precision therapy is expected to provide more benefits to breast cancer patients.

Key words: Breast cancer, Fundamental translational research, Drug resistance mechanisms, Precision therapy, Biomarkers, Immunotherapy

中图分类号: 

相关文章

[1] 林佳琳, 王文娜, 徐兵河. 抗体药物偶联物在乳腺癌领域的研究现状与展望[J]. 中国癌症杂志, 2025, 35(2): 154-166.
[2] 杨鑫, 史钱枫, 刘强. 2024年中国乳腺癌重要临床研究成果[J]. 中国癌症杂志, 2025, 35(2): 167-175.
[3] 黎星, 彭子琪, 于鑫淼, 金锋. 2024年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2025, 35(2): 176-185.
[4] 吴淞, 袁洋, 江泽飞. 2024年改变晚期乳腺癌临床实践的重要研究进展[J]. 中国癌症杂志, 2025, 35(2): 186-194.
[5] 曾成, 王沅怡, 王佳妮, 马飞. 乳腺癌免疫检查点抑制剂治疗的研究进展与探索方向[J]. 中国癌症杂志, 2025, 35(2): 195-204.
[6] 李俊杰. 早期乳腺癌局部治疗与全身治疗的进展与展望[J]. 中国癌症杂志, 2025, 35(2): 205-212.
[7] 王青, 俞育帅, 王晨曦, 姜子荣, 李佳璐, 唐诗聪, 宋传贵. 三级淋巴结构异质性在三阴性乳腺癌新辅助治疗中的预测作用及免疫微环境特征的研究现状与展望[J]. 中国癌症杂志, 2025, 35(2): 213-218.
[8] 逯永晋, 石志强, 李彤, 王永胜, 邱鹏飞. 乳腺癌前哨淋巴结阳性豁免腋窝清扫后区域淋巴结放疗的回顾性研究[J]. 中国癌症杂志, 2025, 35(2): 228-236.
[9] 蔡舒玥, 谢佺, 周雨萱, 刘清竹, 邱玲, 林建国. NRP-1靶向分子探针助力乳腺癌诊断的最新进展及展望[J]. 中国癌症杂志, 2025, 35(2): 249-254.
[10] 耿倩倩, 杨爱民. 碘难治性分化型甲状腺癌的治疗进展及展望[J]. 中国癌症杂志, 2025, 35(1): 30-39.
[11] 李汝平, 杨辉. 放射性碘难治性甲状腺癌的临床试验现状及未来展望[J]. 中国癌症杂志, 2025, 35(1): 40-48.
[12] 林秋玉, 王宇鑫, 林承赫. 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景[J]. 中国癌症杂志, 2025, 35(1): 58-67.
[13] 徐睿, 王泽浩, 吴炅. 肿瘤相关中性粒细胞在乳腺癌发生、发展中的作用研究进展[J]. 中国癌症杂志, 2024, 34(9): 881-889.
[14] 葛祖荫, 宋坤, 林云霄, 钟烨凌, 郝敬铎. 循环肿瘤细胞FCGBP和BIGH3作为结直肠癌潜在生物标志物的可行性研究[J]. 中国癌症杂志, 2024, 34(8): 745-752.
[15] 曹晓珊, 杨蓓蓓, 丛斌斌, 刘红. 三阴性乳腺癌脑转移治疗的研究进展[J]. 中国癌症杂志, 2024, 34(8): 777-784.